purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation nvcr earnings call period ending march image source motley fool novocure nvcr q earnings callmay etcontents prepared remark question answer call participant prepared remark operatorgood day thank standing welcome novocure q earnings conference call operator instruction please advised today conference recorded would like hand conference speaker today ingrid goldbergingrid goldberg vice president finance investor relation good morning thank joining u review novocures first quarter performance joined morning executive chairman bill doyle ceo asaf danziger cfo ashley cordova member executive leadership team available qa reference slide accompanying earnings release found website wwwnovocurecom investor relation page quarterly report start would like remind discussion conference call include forwardlooking statement actual result could differ materially projected statement statement involve number risk uncertainty beyond control described time time sec filing intend update publicly forwardlooking statement except required law appropriate refer nongaap financial measure evaluate business specifically adjusted ebitda measure earnings interest tax depreciation amortization sharebased compensationwe believe adjusted ebitda important metric remove impact earnings attributable capital structure tax rate material noncash item best reflects financial value generated business reconciliation nongaap gaap financial measure included press release earnings slide form k filed sec today material also accessed investor relation page website following prepared remark today open line question turn call executive chairman bill doyle bill doyle executive chairman thank ingrid good morning novocure mission extend survival aggressive form cancer developing commercializing innovative therapy tumor treating field last two decade established ttfields mechanism action developed improved ttfields delivery technology completed multiple successful phase clinical trial treated commercial patient built innovative business model entered ready build foundation pleased report progress today march announced metis phase clinical trial studying benefit treating brain metastasis nonsmall cell lung cancer ttfields therapy met primary endpoint providing statistically significant extension time intracranial progression later year expect fda pma eu ce mark approval ttfields therapy metastatic nonsmall cell lung cancer postplatinum progression fda pma supplement approval nextgeneration array gbm toward end announce topline data phase trial locally advanced pancreatic cancer exciting year novocure many milestone incredibly grateful hard work colleague dedication patient prescribing physician today call begin review commercial business gbm discus clinical trial update quarter close discussion q financial result opening line question first quarter novocure continued steady pace execution finished q new prescription active patient therapy global record organization global commercial team focused lever active patient growth including prescription patient start longterm compliance persistence believe input critical achieving best outcome patient turn believe drive sustainable growth also believe product development enhancement drive improved patient outcome reminder last year successfully introduced nextgeneration array several european country pma supplement new array filed fda december new array lighter thinner flexible leverage new material improve patient experience new patent filed key market protect improved design yous team focused increasing awareness benefit ttfields therapy among potential patient prescribing physician last month launched directtoconsumer campaign power life new print digital asset firstever directtoconsumer television advertising campaign key effort grow gbm business connected television reach yous household educating potential patient caregiver optune gio believe directtopatient messaging raise awareness ttfields therapy strengthen demand patient following diagnosis look ahead one key objective successfully gain approval launch optune lua patient nonsmall cell lung cancer filed regulatory submission major market january fda formally accepted pma filing recently completed day meeting fda critical milestone pma submission day meeting productive indication lunar pma referred panel outside yous awaiting ce mark decision europe substantive discussion japanese regulator pending regulatory approval team focused launch preparation yous germany hired trained thoracic sale team including territory manager clinical educator patientexperienced team within organization preparing opportunity ahead team developing marketing material field team training asset preparing hcp certification resource assembling material future thoracic speaker bureau planning thoracic congress training internal support team prepared hit ground running plan treat patient germany yous immediately following approval using named patient reimbursement process similar way launched treatment gbm country team eager support another large indication hope treat many patient coming month pas phone asaf share regarding clinical pipeline updateasaf danziger chief executive officer thank bill q made strong progress advancing clinical pipeline three main indication start metis march announced phase metis trial metis primary endpoint marking latest positive phase clinical trial reminder metis started ttfields therapy supportive care treatment brain metastasis nonsmall cell lung cancer following stereotactic radiosurgery patient ttfields therapy arm achieved month median time intercranial progression compared month control arm result statistically significant pvalue ratio patient treated ttfields therapy experienced sustained neurocognitive function quality life without increase systemic toxicity metis result meaningful physician patient caregiver many thousand nonsmall cell lung cancer patient suffer brain mets year prognosis poor typically involves rapid neurocognitive decline devastating effect quality life factor motor skill speech mood cognitive ability today limited innovation study brain metastasis treatment option stereotactic radiosurgery risk continuous relapse whole brain radiotherapy risk major neurocognitive toxicity patient population ttfields ability significantly extend time intercranial progression delay need repeat sr sustain neurocognitive function without increasing systemic adverse event offer major benefit key opinion leader validated enthusiasm metis result last week pleased announce metis trial accepted latebreaking session asco annual meeting presented chicago monday rd june metis presentation submitted accepted asco long standard congress deadline validating belief clinical relevance interest study would like express thanks investigator patient involved metis well novocure team supported planning execution trial quarter also announced innovate phase clinical trial result selected best oral presentation asco innovate studied ttfields therapy together paclitaxel platinumresistant ovarian cancer result exploratory subgroup analysis showed pegylated liposomal doxorubicin pldnaive patient treated ttfields therapy paclitaxel saw significant improvement overall survival compared pldnaive patient treated paclitaxel alone total patient enrolled innovate clinical trial patient pldnaive overall survival pldnaive patient randomized receive ttfields therapy paclitaxel month compared month pldnaive patient randomized receive paclitaxel alone pldnaive subgroup baseline demographic similar across cohort analysis may help explain potential survival benefit previously reported innovate patient received one prior line therapy novocure exploring effect doxorubicin tumor tissue potential consequence ttfields dose believe finding contribute deeper understanding mechanism action inform future trial design finally within gbm program completed enrollment trident trial studying overall survival optune gio started chemoradiation compared starting chemoradiation fda approved ind keynote phase clinical trial studying overall survival newly diagnosed gbm patient treated ttfields temozolomide pembrolizumab keynote trial build upon promising clinical data thetop phase trial extensive preclinical research published jci accomplished lot quarter would like reiterate gratitude team look forward future report milestone field ashley share detail first quarter financial performanceashley cordova chief financial officer thank asaf first quarter period consistent execution commercial regulatory progress launch preparation important clinical readout generated million net revenue first quarter year year ended quarter active patient therapy year year revenue growth primarily driven successful launch france improved approval rate yous current period gross margin first quarter sga expense million quarter year year modest increase sale marketing expense driven sale force expansion increased marketing activity anticipation potential launch nonsmall cell lung cancer investment partially offset lower personnel expense within ga rd expense quarter million year year decrease driven primarily lower personnel expense timing activity within ongoing clinical trial portfolio net loss first quarter million per share adjusted ebitda negative million increase million compared first quarter last year increase adjusted ebitda primarily driven revenue growth associated increase gross margin action taken november restructuring heightened focus driving operational efficiency reduced total operating expense excluding sharebased compensation million year year intend take action prioritize growth maintain financial health flexibility position novocure future profitability cash shortterm investment totaled million march morning announced entered new fiveyear senior secured credit facility affiliate pharmakon advisor million first million tranche issued closing second million tranche issued june additional million available drawn across two tranche novocures discretion subject certain milestone march proceeds used settle upon maturity novocures convertible note fund working capital need stemming novocures anticipated launch nonsmall cell lung cancer full term deal outlined today q importantly transaction strengthened cash position solidified balance sheet nondilutive capital number exciting milestone horizon multitranche delayed draw debt facility provides u valuable balance sheet flexibility novocure appreciate importance balancing growth profitability watchful eye achieving objective would like close today highlighting one optune gio user kelvin doc sinclair sacramento california doc man many passion composes music collect mineral raise coin operates bodybuilding gym home enjoys spending time wife terra three child seven grandchild february doc diagnosed glioblastoma discussion physician considerable research doc decided optune gio right optune gio helped doc continue active lifestyle without sacrifice numerous hobby people like doc remind u mean extend patient survival aggressive cancer like glioblastoma exciting slate potential catalyst approaching metastasis presentation asco upcoming regulatory decision lunar ce mark europe pma submission yous pma supplement new array finally topline data phase panova trial pancreatic cancer team head focused execution look forward updating throughout year hand back operator question question answer operatorthank operator instruction first question come jason bednar piper sandler line openjason bednar piper sandler analyst hey good morning congrats result today team wanted first start nonsmall cell good hear think face advisory committee panel good sign item share day meeting fda feedback early indication fda given submission kind related know hoping get ce mark ahead pma approval similar question fda interaction anything discus respect conversation regulatory body europeasaf danziger chief executive officer day meeting productive meeting review mainly labeling thing put right place expecting continue interaction fda mentioned believe another meeting regarding european continue discussion regulator basically ongoing discussion expecting first half year get see jason bednar piper sandler analyst ok change ce mark timeline still within next couple month good launch france clearly going well seems driving lot upside script active patient growth accelerating another good leading indicator possible look international market hear update today see commercial launch year kind stand plan major european market currently presencefrank leonard president yous central nervous system cancer frank yeah first would reiterate pleased progress made france opened market conducted launch see number seeing france size around germany size opportunity term revenue continue work additional market kind give update market become line sight specific milestone pas along direct update right continue look additional opportunitiesjason bednar piper sandler analyst right maybe one quick followup one housekeeping one ashley frank guess timeline willing share market prioritizing trying get sense something maybe coming later year next year market think ashley apology busy morning lot report really chance go full debt term help u rate paying debt want confirm planning settle convert fully cash come due next year planfrank leonard president yous central nervous system cancer jason frank answer market question first going provide specific timeline today think term market said looking big market europe obviously working multiple different area italy spain mix get closer real milestone pas alongashley cordova chief financial officer jason clean housekeeping thanks question remind everybody announce morning signed new fiveyear senior secured credit facility pharmakon partner know well million facility million committed draw million drew morning million draw june next year million draw discretion term sofr plus floating rate facility anticipation full use proceeds settle convertible note become due november fund working capital need nonsmall cell lung cancer believe sufficient fully remove cash overhang related settlement convertible note kind eye ahead looking balance sheet carry u strategic planjason bednar piper sandler analyst perfect thanks much congrats againoperatorthank next question come jonathan chang leerink partner line openjonathan chang leerink partner analyst hi guy good morning thanks taking question two question first metis study congrats getting latebreaker asco help set expectation ahead asco presentationnicolas leupin chief medical officer jonathan good morning nicolas thank question know metis phase trial brain metastasis nonsmall cell lung cancer come huge amount data show topline result initial analysis still working rest would kindly invite come see u five weeksjonathan chang leerink partner analyst got maybe also second question metis study secondary endpoint appreciate limited say today able least help u rule possibility endpoint trending wrong directionnicolas leupin chief medical officer think direct asco far really excited show demonstrate superiority ttfields areajonathan chang leerink partner analyst understood thanks taking questionsoperatorthank next question come jessica fye jp morgan chase line openna sun jpmorgan chase company analyst good morning guy na sun jessica fye question look metis study consider commercial opportunity brain mets like given seen study current expectation sort peak commercial opportunity indication second think interesting guy decided go ahead another pancreatic indication driven seeing phase panova study decided start another study pancreatic indication meashley cordova chief financial officer na actually maybe start market sizing update data inaudible pas frank provide additional clarity commercial opportunity metis avoidance doubt though within pancreatic want say always panova trial ongoing part ongoing pipeline one excited committed part longterm strategy update successful open enrolling trial regard market size metis significant opportunity patient brain mets diagnosed brain mets diagnosis nonsmall cell lung cancer approximately nonsmall cell lung cancer patient develop brain mets point course disease journey large population admittedly also heterogeneous patient population patient population focus treatment primary tumor systemic therapy time managing mets recommending take conservative estimate lot precedent systemic therapy treatment brain mets noted company go space recommend conservative case recommending model patient annually yous opportunity set start think able explore grow anchoring expectationsfrank leonard president yous central nervous system cancer yeah frank add color term hearing customer reaction data strong reaction positive sentiment think highlight accepted latebreaker asco seen pi part study well customer treat glioblastoma reach engaged interest see area high unmet needsoperatorthank one moment next question next question come vijay kumar evercore isi line openkevin joaquin evercore isi analyst hi kevin vijay followup question meeting fda fda explicitly indicates need ad hoc panel meeting opportunity fda come back ask accountasaf danziger chief executive officer thank question fda many thing principle panel state supposed know meeting panel mentioned option still believe panelkevin joaquin evercore isi analyst got panova timeline look like data expected second half year changed versus prior expectation fourth quarterbill doyle executive chairman yeah nothing changed stage announced trial bill way announced last patient trial designed read month following last patient still track read data cleaned change expectation panovakevin joaquin evercore isi analyst thank youoperatorthank one moment next question next question come emily bodnar hc wainwright line openemily bodnar hc wainwright company analyst hi good morning thanks taking question congrats progress curious could provide timing potential pma submission based metis study separately potential new indication kind looking advance laterstage study major phase study kind coming end thank youashley cordova chief financial officer hey emily think transparently soon point metis data fresh analysis looking range option given current indication footprint would like go disease simply soon comment timing update news would actually offer message pipeline committed executing pipeline commitment shared last year strategic prioritization shared november clearly advancing gbm opportunity extend survival gbm trident trial keynote trial continuing invest lung also focusing pancreatic cancer know done platform therapy believe significant broad applicability focused today come back update thememily bodnar hc wainwright company analyst make sense thanksoperatorthank question time would like turn back bill doyle closing remarksbill doyle executive chairman thank everyone joining morning continued interest novocure q quarter real executional progress pleased milestone achieved including course metis hitting primary endpoint acceptance latebreaker present first analysis asco pleased asaf described day meeting fda stand regulatory process yous europe trident important study u pleased enrollment complete timing period releasing data always working fda achieve milestone like ind approval important milestone term getting exciting trial course based thetop data immune checkpoint inhibitor ground finally financing know received bunch question going retire convertible debt balance sheet good term underline think financing announced morning answered question made clear intend proceed path profitability big thanks owed thanks everyone team thanks patient prescribers lot come look forward updating progress future call good dayoperatoroperator signoff duration minutescall participantsingrid goldberg vice president finance investor relationsbill doyle executive chairmanasaf danziger chief executive officerashley cordova chief financial officerjason bednar piper sandler analystfrank leonard president yous central nervous system cancersjonathan chang leerink partner analystnicolas leupin chief medical officerna sun jpmorgan chase company analystkevin joaquin evercore isi analystemily bodnar hc wainwright company analyst nvcr analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position recommends novocure motley fool disclosure policy